BUZZ-Tekmira Pharmaceuticals Corp: Up on research action

Mon Aug 18, 2014 8:57am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

** Drug developer's U.S.-listed shares up 8.7 pct at $19.61 premarket

** Leerink Swann LLC starts covering stock with "outperform" rating and $25 price target

** "We believe Tekmira's (lipid-nanoparticle nucleic acid) platform represents a best-in-class technology that has been clinically validated," analyst Michael Schmidt writes in note

** Of 3 other analysts covering stock, 1 has "strong buy" rating and 2 have "buy"

** Median price target on stock is $26.25, down from $28.75 two months ago